Rao A, et al. - Researchers performed a large-scale analysis of survival trends in the tyrosine kinase inhibitors (TKI) era to determine their impact on outcomes for advanced renal cell carcinoma (RCC) patients. Between 2000 and 2013, the Surveillance, Epidemiology and End-Results (SEER) database was queried for adult patients with advanced RCC diagnosed. They performed Kaplan-Meier survival and multivariate Cox proportional hazards analyses for this investigation. This research provided a largest registry-based analysis of survival outcomes in the TKI era. The survival has improved significantly with the advent of TKIs as standard of care therapy in the majority of patients. Findings revealed that survival for patients with non-clear cell RCC is clearly worse than clear-cell RCC and does not appear to have changed with TKIs. They reported that elderly patients, women, and Black patients seem to have worse outcomes.